Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NervGen Pharma ( (TSE:NGEN) ) just unveiled an update.
NervGen Pharma announced groundbreaking results from its Phase 1b/2a CONNECT SCI Study, showing that its pharmacologic candidate, NVG-291, significantly improved corticospinal connectivity and restored meaningful function in patients with chronic spinal cord injuries. This marks a pivotal advancement in spinal cord injury treatment, as the company aims to redefine the standard of care and pursue expedited regulatory pathways with the FDA to accelerate access to NVG-291.
The most recent analyst rating on (TSE:NGEN) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.
Spark’s Take on TSE:NGEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:NGEN is a Neutral.
NervGen Pharma presents a high-risk, high-reward profile typical of early-stage biotech firms. Financial performance is weak due to ongoing R&D costs with no revenue, but technical indicators show positive momentum. Corporate events highlight potential upside from clinical advancements. However, the lack of earnings and reliance on financing remain significant concerns.
To see Spark’s full report on TSE:NGEN stock, click here.
More about NervGen Pharma
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurologic disorders.
Average Trading Volume: 143,125
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$268.2M
Find detailed analytics on NGEN stock on TipRanks’ Stock Analysis page.